drugset
drugset / Trial / NCT03880123

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

NCT03880123 ↗

Phase 1 Withdrawn Matthew Ingham Karyopharm Therapeutics Inc · collabTakeda · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to establish a safe and tolerable dose combination (the "maximum tolerated dose") of selinexor and ixazomib when used together for the treatment of patients with certain types of advanced sarcoma. The study will enroll patients with advanced dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. Future studies to further evaluate the safety and anti-cancer efficacy of this treatment for sarcoma will use the dose combination determined in this study.

Timeline

Start
2020-11
Primary completion
2020-11-24
Completion
2020-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 4 mg Oral
Subject Selinexor Other / unclassified 40 mg Oral
Subject Selinexor Other / unclassified 60 mg Oral
Subject Selinexor Other / unclassified 80 mg Oral
Subject Selinexor Other / unclassified 100 mg Oral

Indications

Ewing sarcoma alveolar soft part sarcoma liposarcoma malignant peripheral nerve sheath tumor